Diamonds star left ‘in agony' as NZ move lasts just three games in ‘big blow' for her team
The star goal shooter's return to play now remains unclear, with Diamonds medical staff to be consulted on the best option for the 31-year-old.
Watch every game of the 2025 Suncorp Super Netball season, LIVE on Kayo. New to Kayo? Get your first month for just $1. Limited time offer.
Wallam, playing for the Northern Mystics, had been attempting to keep the ball in play off a rebound when she turned to shoot and fell awkwardly, landing on her left arm.
It's the same arm Wallam broke while playing under Dan Ryan in England for the Leeds Rhinos before she would go on to light up Super Netball and earn a fairytale Australian call up.
Wallam's injury late in the third term of her side's thrilling win over the Southern Steel was described as a 'big, big blow' for the Mystics.
'She took a hard fall,' commentator Jeff McTainsh said.
'She's coming off here, not happy. She landed hard trying to keep it in.
'Just tried to break her fall Wallam, stuck out her left wrist.
'A big, big blow for the Northern Mystics.'
Fellow commentator Kruze Tangira said his 'heart dropped' watching Wallam immediately clutch at her injured wrist.
'My stomach was in knots seeing that,' Tangira said.
'She tried to attempt that shot and just fell heavily on her left wrist.
'She was attempting to get the ball back in, we've seen that in previous games where she does a little flick behind the post.
'As soon as it happened, she grabbed that left wrist obviously in agony.'
Wallam stayed on court for almost a minute before she was able to head to the bench and not return for the remainder of the contest.
The Aussie star recruit was clearly in pain as she made her way from the court.
In a statement released on Tuesday, the Mystics confirmed Wallam would be sidelined indefinitely.
'Donnell Wallam is currently undergoing treatment for a hand injury that she suffered in the Mystics Round 3 clash with the Southern Steel,' the club said.
'Donnell will be seeing a hand specialist this week and a return to play plan will be confirmed following consultation with Mystics and Australian Diamonds medical teams.
'We wish Donnell a speedy recovery and can't wait to have her back on court.'
Wallam was only in her third game across the ditch after moving on from Super Netball when not offered a deal at the Queensland Firebirds.
The goal shooter was sitting inside the league's top five for goals scored – alongside fellow Aussie recruit Charlie Bell at the Stars – before she suffered the arm injury.
Wallam is the player who replaced Super Netball's superstar recruit Grace Nweke at the three-time ANZ Premiership champions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 hours ago
- News.com.au
ASX Health Quarterly Wrap: PainChek grows aged care presence, EMVision starts pivotal trial
It's 31 July, marking the official close of the June quarterly reporting period under ASX Listing Rules. For healthcare companies, these filings set the stage for full-year financial results following the end of the Australian financial year. Investors have been watching closely for signs of revenue growth, cash burn rates, and strategic progress across a sector that's starting to regain momentum after a challenging few years. Higher interest rates, tighter funding, and a shift toward value stocks have weighed on growth sectors like healthcare. While the broader market rose 10%, the ASX healthcare sector decline 4% in FY25 but there are positive signs in the first month of FY26. The S&P/ASX 200 Health Care Index (ASX:XHJ) surged 5.4% last week, extending a 5% gain from the week prior and continuing its upward trajectory this week. PainChek (ASX:PCK) PainChek, the developer of a smart device-based pain assessment and monitoring application, continued to scale its presence in the global aged care market, reporting a base of 110,000 contracted licences across more than 1900 facilities in Australia, New Zealand, the UK and Canada. Once fully implemented, these contracts represent an annual recurring revenue (ARR) of $5.4 million, up 10% from the prior quarter contracted licences. As of June 30, the company had 71,000 implemented licences, generating $3.6 million ARR, a 17% increase on the prior year. Global customer retention remains strong at over 85%, with a net revenue retention rate of 106%, which PainChek said reflected expansion with existing clients as they themselves expand. Customer receipts for FY25 totalled $3.49m, including a record $1.02m in the June quarter, the first time quarterly receipts have exceeded the $1m mark. Recognised (unaudited) revenue for the 12 months to March 2025 came in at $3.36m, up 26% YoY while R&D grant income reached $1.41m PainChek also completed a $7.5m capital raise in July, which will support growth plans in North America and marketing of its new PainChek Infant App, now launched in Australia. In the US, Nick Garofoli was appointed head of business development to support its entry into the country's $582m long term care market with PainChek Adult. Garofoli has more than 15 years of leadership experience in technology, with a particular focus on aged care and senior living sectors. Cumulative global pain assessments have now surpassed 12.17m, up 103% on the prior year, building on what PainChek said was a unique and expanding clinical database. New contract models, including upfront payments and fixed activations, are helping accelerate implementation and improve cash flow for the company. Post quarter on July 21, PainChek completed its final submission to the US Food and Drug Administration (FDA) for de novo clearance for the PainCheck Adult App as a medical device in the US. PainCheck said its expects a financial decision within 75 days, giving a potential clearance date of "between late September to early October, 2025, if not sooner". The June quarter was significant for EMVision with start of a pivotal validation trial for its first commercial device, the emu bedside brain scanner to diagnose stroke in March. Recruitment is underway at five leading sites, including in Australia and the US for the validation trial to support FDA de novo clearance. The company has also launched a continuous innovation study to enhance stroke and traumatic brain injury evaluation features. EMVision's second product – its portable device to detect strokes and traumatic brain injury First Responder – also underwent successful aeromedical proof-of-concept testing during the quarter. A series of volunteer scans were taken in remote Australian settings in collaboration with the Royal Flying Doctor Service (RFDS) and Australian Stroke Alliance (ASA). Post quarter end EMVision received ethics approval for two studies that will advance First Responder prototype. The studies are designed to demonstrate that the device can fit seamlessly into emergency workflows and collect valuable data in the pre-hospital setting. The company also received an Australian government Industry Growth Program (IGP) Commercialisation and Growth Grant for $5m to fast-track commercialisation of the First Responder. EMVision is continuing to pursue a non-dilutive grant funding strategy across international, federal and state channels. During the quarter EMVision announced appointment of Ramsay Health Care (ASX:RHC) former CEO of Ramsay Australia Carmel Monaghan as non-executive director. The company has also increased its head office premises to expand production capabilities, including establishment of a pilot commercial production line for the First Responder device. As part of its market engagement and education strategy EMVision is showcasing its technology at leading scientific and industry events including with long-term collaborators such as ASA and NYSE-listed Keysight Technologies. It's pivotal trial has been accepted for an oral presentation at the World Stroke Congress in Spain in October. EMVision's tech will also be presented at the US Military Health System Research Symposium in August, presenting an opportunity for the company to introduce its tech for potential point-of-car TBI diagnosis. The company had $10.5m cash at June 30, 2025 and also o secured a $400,000 milestone grant post-quarter and has $4.4 million in additional non-dilutive funding available, alongside an anticipated FY25 R&D tax rebate due later this year. Clever Culture continued to build momentum during the June Quarter with big pharma AstraZeneca progressing to routine use of its APAS Independence instruments, which remain the only US FDA-cleared AI technology for automated culture plate reading. After successfully validating the APAS Independence for 90mm settle plates, AstraZeneca now has nine installed across global sites. Post quarter in July Novo Nordisk placed an order for one of the instruments as part of a group evaluation as Clever Culture continues to target big pharma in its growth strategy. Sales opportunity from existing customers now exceed $40m with five existing customers represent opportunity of 60 to 80 APAS instruments, equating to $36m-$48m of potential upfront sales revenue and $7m-$9m in annual recurring revenues. The company has been developing new 55mm settle plates to double the capability of the APAS instruments. The company said instrument hardware and software has been completed with AI analysis module and launch targeted for August. The company ended the June quarter with a cash balance of $1.3m, and $3.8m in known/committed cash inflows expected over the next two quarters. "Fiscal year 2025 has been a turning point for the company, resulting in a major milestone towards becoming a sustainably profitable business," CEO and managing director Brent Barnes said. "Importantly, this is just the first year of establishing APAS®Independence in the pharmaceutical manufacturing market. "We launched with the ability to automate approximately 50% of environmental monitoring tests through our settle plate capability.
The Advertiser
6 hours ago
- The Advertiser
Fever reveal driving force behind dominant campaign
West Coast Fever coach Dan Ryan has revealed last year's heartbreaking one-goal preliminary final loss to the Melbourne Vixens has been the driving force behind his team's record-breaking 2025 campaign. The Fever and Vixens are the fiercest of rivals, and will face off for Super Netball title glory in Saturday's grand final at Rod Laver Arena. West Coast are on a league-record 13-match winning run, with their 77-45 demolition of the NSW Swifts in the major semi-final their best performance of the season. That display earned the Fever a week off. The Vixens will also enter the decider brimming with confidence after coming from 10 goals down in the last quarter to beat the Swifts 66-65 last week. The Fever and Vixens boast arguably Super Netball's fiercest rivalry. The Vixens beat West Coast 66-64 in the 2020 grand final, before the Fever returned the favour in the 2022 decider with a crushing 70-59 triumph. But the pain of losing last year's preliminary final 73-72 to the Vixens still burns strong for the Fever, and they'll get the chance for revenge on Saturday night. "If we look at the prelim final last year, that's really been the driving force behind this year's campaign - addressing the gaps that we needed to close across the course of the season," Ryan said. "It's a grand final, so it does bring out the best teams. "Whilst we've won by 10 and 11 respectively (this season) we have to anticipate a goal for goal battle that goes right down to the wire." The Fever (12-2) finished on top of the ladder, while the Vixens (8-6) only just scraped into fourth. But under Super Netball's controversial policy of selling the grand final hosting rights before each season, Melbourne will have home-court advantage given the match is being played at Rod Laver Arena. Not that you'll catch the Fever crying foul about it. "I think it poses an even greater challenge that we're all really excited by, to beat the Vixens on their home court," Ryan said. "Every time we've had an away game in the home-and-away season, we've acknowledged that if we're going to win the competition, we have to do it away from home. "I've got great confidence in our group that we can stay really tight in that Fever bubble and stay really locked in and laser-focused about what we need to do together." The Fever, led by superstar goal shooter Jhaniele Fowler-Nembhard, will enter the decider as hot favourites - a mantle Ryan is embracing. West Coast Fever coach Dan Ryan has revealed last year's heartbreaking one-goal preliminary final loss to the Melbourne Vixens has been the driving force behind his team's record-breaking 2025 campaign. The Fever and Vixens are the fiercest of rivals, and will face off for Super Netball title glory in Saturday's grand final at Rod Laver Arena. West Coast are on a league-record 13-match winning run, with their 77-45 demolition of the NSW Swifts in the major semi-final their best performance of the season. That display earned the Fever a week off. The Vixens will also enter the decider brimming with confidence after coming from 10 goals down in the last quarter to beat the Swifts 66-65 last week. The Fever and Vixens boast arguably Super Netball's fiercest rivalry. The Vixens beat West Coast 66-64 in the 2020 grand final, before the Fever returned the favour in the 2022 decider with a crushing 70-59 triumph. But the pain of losing last year's preliminary final 73-72 to the Vixens still burns strong for the Fever, and they'll get the chance for revenge on Saturday night. "If we look at the prelim final last year, that's really been the driving force behind this year's campaign - addressing the gaps that we needed to close across the course of the season," Ryan said. "It's a grand final, so it does bring out the best teams. "Whilst we've won by 10 and 11 respectively (this season) we have to anticipate a goal for goal battle that goes right down to the wire." The Fever (12-2) finished on top of the ladder, while the Vixens (8-6) only just scraped into fourth. But under Super Netball's controversial policy of selling the grand final hosting rights before each season, Melbourne will have home-court advantage given the match is being played at Rod Laver Arena. Not that you'll catch the Fever crying foul about it. "I think it poses an even greater challenge that we're all really excited by, to beat the Vixens on their home court," Ryan said. "Every time we've had an away game in the home-and-away season, we've acknowledged that if we're going to win the competition, we have to do it away from home. "I've got great confidence in our group that we can stay really tight in that Fever bubble and stay really locked in and laser-focused about what we need to do together." The Fever, led by superstar goal shooter Jhaniele Fowler-Nembhard, will enter the decider as hot favourites - a mantle Ryan is embracing. West Coast Fever coach Dan Ryan has revealed last year's heartbreaking one-goal preliminary final loss to the Melbourne Vixens has been the driving force behind his team's record-breaking 2025 campaign. The Fever and Vixens are the fiercest of rivals, and will face off for Super Netball title glory in Saturday's grand final at Rod Laver Arena. West Coast are on a league-record 13-match winning run, with their 77-45 demolition of the NSW Swifts in the major semi-final their best performance of the season. That display earned the Fever a week off. The Vixens will also enter the decider brimming with confidence after coming from 10 goals down in the last quarter to beat the Swifts 66-65 last week. The Fever and Vixens boast arguably Super Netball's fiercest rivalry. The Vixens beat West Coast 66-64 in the 2020 grand final, before the Fever returned the favour in the 2022 decider with a crushing 70-59 triumph. But the pain of losing last year's preliminary final 73-72 to the Vixens still burns strong for the Fever, and they'll get the chance for revenge on Saturday night. "If we look at the prelim final last year, that's really been the driving force behind this year's campaign - addressing the gaps that we needed to close across the course of the season," Ryan said. "It's a grand final, so it does bring out the best teams. "Whilst we've won by 10 and 11 respectively (this season) we have to anticipate a goal for goal battle that goes right down to the wire." The Fever (12-2) finished on top of the ladder, while the Vixens (8-6) only just scraped into fourth. But under Super Netball's controversial policy of selling the grand final hosting rights before each season, Melbourne will have home-court advantage given the match is being played at Rod Laver Arena. Not that you'll catch the Fever crying foul about it. "I think it poses an even greater challenge that we're all really excited by, to beat the Vixens on their home court," Ryan said. "Every time we've had an away game in the home-and-away season, we've acknowledged that if we're going to win the competition, we have to do it away from home. "I've got great confidence in our group that we can stay really tight in that Fever bubble and stay really locked in and laser-focused about what we need to do together." The Fever, led by superstar goal shooter Jhaniele Fowler-Nembhard, will enter the decider as hot favourites - a mantle Ryan is embracing.
Perth Now
6 hours ago
- Perth Now
Fever reveal driving force behind dominant campaign
West Coast Fever coach Dan Ryan has revealed last year's heartbreaking one-goal preliminary final loss to the Melbourne Vixens has been the driving force behind his team's record-breaking 2025 campaign. The Fever and Vixens are the fiercest of rivals, and will face off for Super Netball title glory in Saturday's grand final at Rod Laver Arena. West Coast are on a league-record 13-match winning run, with their 77-45 demolition of the NSW Swifts in the major semi-final their best performance of the season. That display earned the Fever a week off. The Vixens will also enter the decider brimming with confidence after coming from 10 goals down in the last quarter to beat the Swifts 66-65 last week. The Fever and Vixens boast arguably Super Netball's fiercest rivalry. The Vixens beat West Coast 66-64 in the 2020 grand final, before the Fever returned the favour in the 2022 decider with a crushing 70-59 triumph. But the pain of losing last year's preliminary final 73-72 to the Vixens still burns strong for the Fever, and they'll get the chance for revenge on Saturday night. "If we look at the prelim final last year, that's really been the driving force behind this year's campaign - addressing the gaps that we needed to close across the course of the season," Ryan said. "It's a grand final, so it does bring out the best teams. "Whilst we've won by 10 and 11 respectively (this season) we have to anticipate a goal for goal battle that goes right down to the wire." The Fever (12-2) finished on top of the ladder, while the Vixens (8-6) only just scraped into fourth. But under Super Netball's controversial policy of selling the grand final hosting rights before each season, Melbourne will have home-court advantage given the match is being played at Rod Laver Arena. Not that you'll catch the Fever crying foul about it. "I think it poses an even greater challenge that we're all really excited by, to beat the Vixens on their home court," Ryan said. "Every time we've had an away game in the home-and-away season, we've acknowledged that if we're going to win the competition, we have to do it away from home. "I've got great confidence in our group that we can stay really tight in that Fever bubble and stay really locked in and laser-focused about what we need to do together." The Fever, led by superstar goal shooter Jhaniele Fowler-Nembhard, will enter the decider as hot favourites - a mantle Ryan is embracing.
